In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC).

Watch the video and download the accompanying slides to learn about:

  • The considerations for treatment selection in clinical practice to minimise the impact on patients' lives
  • Applying recent data to treatment sequencing in bone-dominant mCRPC
  • Educating and supporting patients during treatment so they know what to expect

 

Clinical Takeaways

  • Radiopharmaceuticals such as radium-223 and 177Lu-PSMA-617 offer a survival benefit to mCRPC patients as well as managing bone pain and QOL

  • They are able to deliver targeted radiation to prostate cancer cells, thereby minimising toxicity to normal healthy tissue

  • Real-world data support using 177Lu-PSMA in patients who previously received Ra-223

  • Nurses and patients should be aware of post-treatment precautions, but radiopharmaceuticals are an effective and manageable treatment option for mCRPC patients

 

Janet Forgenie works at University College Hospital London as a Uro-oncology CNS managing patients with organ confined disease as well as metastatic disease having chemotherapy, radiotherapy and immunotherapy treatments primarily for prostate but also with bladder and penile cancer. She has a specialist interest in penile cancer patients who undergo extensive treatment regimens with complex health care needs. Over the years as a uro-oncology CNS Janet has been involved in setting up patient support groups and information seminars for radiotherapy patients which have proven very successful. She has also been involved in an exercise pilot for prostate patients on hormone treatments to encourage exercise to help manage some of the unpleasant side effects from hormones, such as bone health, body image and weight gain. Her background of diagnostic urology has helped extensively in the management of prostate cancer patients, and as a nurse prescriber Janet feels this has been invaluable in the development of a truly independent nurse led service. Janet started her nursing career in Canterbury Kent, achieving her Nursing Diploma in 1994 and Degree in 1997. During her nursing career Janet has worked primarily within urology and oncology, and her current role as a Uro-oncology CNS that combines both specialities is ideal. Janet’s urology experience has been extensive over the past 26 years, working with benign urology as well as oncology urology. She has experience with diagnostic urology, urodynamics and continence and bladder function and has also been involved in pathway development and service development. Janet also has three years of oncology experience, one of which was spent in Australia working with chemotherapy patients and the other two working on an inpatient chemotherapy ward.

Janet Forgenie has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

A novel therapeutic framework 

Experts
Dr Komal Jhaveri, Oncology Brothers (Moderators)
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
patient-support Patient Support

Episode

1

of 2

episode
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
ESDO
Digestive Cancers Europe
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Amgen.